Roche logo — We advance science so that we all have more time with the pe...

Roche

We advance science so that we all have more time with the people we love. Are you ready to join us?

Founded 1998 Switzerland Switzerland 108149 employees IPO Total: $19.91B Pharmaceutical

General Information

Company Name Roche
Founded Year 1998
Location Switzerland Switzerland +24
Employees 108149
Industries Pharmaceutical
Funding Stage IPO
Social

Get notified when Roche moves

Funding, new markets, leadership changes, hiring surges — one e-mail, only when something happens.

Free · no account needed

Recorded by Bounce Watch from public sources. Every entry below carries the date we observed it, and when we have not looked recently the page says so rather than leaving silence to imply nothing happened.

New Partnership Sep 01, 2026

Roche, through its program Roche Commissions, has partnered with Lucerne Festival and the Lucerne Festival Academy to create space for leading contemporary composers.

Event Participation Sep 01, 2026

Roche participated in and supported the APVRS2026 Congress, held over three days on the Gold Coast in Australia, to exchange knowledge on ophthalmology.

Pivot Announced Aug 18, 2026

Roche pRED announced a pivot in its ophthalmology pipeline, shifting from slowing disease progression to transformative vision restoration in advanced retinal disease.

AI Insight

Bounce Watch AI
2 weeks ago

Roche is undertaking a significant strategic pivot in its ophthalmology pipeline, shifting from a focus on slowing disease progression to an ambitious pursuit of transformative vision restoration for advanced retinal diseases. This bold reorientation highlights its commitment to pioneering high-impact, innovative therapies and is supported by continued engagement in key industry events. Backed by robust post-IPO funding, Roche is signaling an intensified push for breakthrough medical solutions.

Signal Types
Strategy Shift R&D Focus Event Participation
Strategic Labels
R&D Reorientation Transformative Innovation Ophthalmology Focus
Next Move: R&D Acceleration
·
Impact: 9/10
·
Ideal For: Public Healthcare Investors

About Roche

Roche, founded in 1896, is a prominent player in the Pharmaceutical industry, headquartered in Switzerland. As a global leader in both pharmaceuticals and diagnostics, Roche combines these strengths to pioneer advancements in personalised healthcare. The company excels in providing targeted treatments across various sectors, including oncology, immunology, and infectious diseases.

With a status as the world’s largest biotech company, Roche offers truly differentiated medicines. Its leadership in in vitro diagnostics and tissue-based cancer diagnostics, alongside diabetes management, underscores its comprehensive healthcare prowess. Significantly, thirty of Roche’s medicines are recognized on the World Health Organization Model Lists of Essential Medicines, highlighting their global impact.

Recently, on March 1, 2026, Roche secured a $7.50B Post IPO Debt investment from Deutsche Bank, emphasizing its financial stability and growth potential. Consistently demonstrating sustainability, Roche has maintained its position as the Group Leader in sustainability for a decade within the Pharmaceuticals, Biotechnology & Life Sciences Industry according to the Dow Jones Sustainability Indices.

Taxonomy: pharmaceuticals, diagnostics, personalised healthcare, oncology, immunology, infectious diseases, ophthalmology, central nervous system, in vitro diagnostics, cancer diagnostics, diabetes management, clinical stage development, neurology, cardiology

Services & Products

Pharma Solutions
Diagnostics Solutions
Product Development
Disease Prevention and Cure

Target Customers

Patients Healthcare Professionals Medical Researchers Health Systems Developing Countries

Funding Rounds & Investors (9)

View All
Funding Stage Amount Investors Lead Investors Date
Post Ipo Debt •••••• 1
Investor
01 Mar 2026
Post Ipo Debt •••••• 1
Investor
01 Dec 2025
Post Ipo Debt •••••• - 01 Nov 2023
Post Ipo Equity •••••• 1
Investor
01 Aug 2021
Post Ipo Equity •••••• 1
Investor
01 May 2020

View All 9 Funding Rounds

Roche Alternatives & Competitors

View All Alternatives
Roche vs
LumiraDx
LumiraDx United Kingdom

Transforming community-based healthcare through POC diagnostics & making lab-comparable tests access...

IPO
316 employees
Health Care, Medical Devices
Roche vs
Roche
Roche Switzerland

A healthy Sweden, where all knowledge is put to use.

106552 employees
Biotechnology, Health Care
Roche vs

Monogram Biosciences, a LabCorp company, is a leader in developing and commercializing innovative pr...

202 employees
Biotechnology, Health Care

FAQ About Roche

We advance science so that we all have more time with the people we love. Are you ready to join us?
Roche was founded in 1998.
Roche is headquartered in Switzerland.
Roche operates in the following industries: Pharmaceutical.
Roche has approximately 108149 employees.
Roche has completed 9 funding rounds, raising a total of $19.91B. The latest funding stage is IPO.
Roche offers: Pharma Solutions, Diagnostics Solutions, Product Development, Disease Prevention and Cure.
Top alternatives and competitors to Roche include LumiraDx, Roche, Monogram Biosciences, Exact Sciences, Dionex Corporation. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
Roche and LumiraDx are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Don't just browse. Track.

Signal Tracker monitors Roche and millions of companies for funding rounds, hiring surges, product changes, and 40+ signal types — so you never miss an opportunity.

One analytics cookie (Google Analytics). Cookie Policy